A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin Lymphoma

Abstract
SOC for newly diagnosed and untreated participants with early-stage Hodgkin Lymphoma is a combination of 4 chemo drugs (ABVD), sometimes followed by radiotherapy. This trial investigates if swapping one of the drugs in ABVD for brentuximab vedotin improves SOC for early-stage HL. This regime is called A2VD. Advanced stage HL patients, treated with A2VD slightly reduced the risk of lymphoma coming back (relapsing) compared with ABVD.
Link
https://hdl.handle.net/10137/12787
Subject
Hodgkin Lyphoma
Title
A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin Lymphoma
Type of document
Interventional/Clinical trials research
Entity Type
Project

Files:

NameSizeformatDescriptionLink
https://digitallibrary.health.nt.gov.au/nthealthserver/api/core/items/0cf65712-1aea-4960-ae80-a395b566143a